ZURICH (Reuters) - Relief Therapeutics Holding expects top-line data from a trial of RLF-100 used intravenously in patients with COVID-19 to be released this month, the Swiss company said on Monday.
“The statistical analysis of the data remains ongoing. Relief expects top-line data from this trial to be reported once the required statistical analyses have been completed,” it said, while affirming that collaboration partner NeuroRx Inc has initiated a phase 2/3 clinical trial investigating the role of inhaled RLF-100TM for treating of patients with severe COVID-19.
Reporting by Michael Shields; Editing by Caroline Copley
Our Standards: The Thomson Reuters Trust Principles.